Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per ...
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug Nuvectis Pharma, Inc. (NASDAQ: NVCT) stock is trading lower after the company reported ...